Skip to content

US · AFJKR · SHELL COMPANIES

Aimei Health Technology Co., Ltd (AFJKR) intrinsic value and stock valuation

$0.10as of 2026-11-21 · Mkt cap 882.14K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aimei Health Technology Co., Ltd DCF and intrinsic value

InvestorsCraft values AFJKR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AFJKR’s statements →

Aimei Health Technology Co., Ltd Graham Number

Graham Number: $3.42d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Shell Companies New York City, NY 10022 aimeihealth.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$0.00
20232025
Net income
$1.06M
20232025
Free cash flow
-$-570K
20232025
Total equity
$8.04M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$0.00$0.00$0.00
Operating income-$-840K-$-1.06M-$-30K
Net income$1.06M$2.55M$170K
EPSd$261.7K$282.4K$18.8K
Operating cash flow-$-570K-$-670K$0.00
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-570K-$-670K$0.00
Total assets$12.1M$73.8M$70.5M
Total debt$2.02M$230K$0.00
Net debt$2.02M$200K-$-580K
Total equity$8.04M$72.3M$69.8M
Cash and short-term investments$0.00$30K$580K
Income statement
202520242023
Revenue$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Research and development expenses$0.00$0.00$0.00
Selling, general and administrative expenses$840K$0.00$30K
Other expenses$0.00$1.06M$0.00
Operating expenses$840K$1.06M$30K
Cost and expenses$840K$1.06M$30K
Interest income$1.9M$3.62M$200K
Interest expense$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00
Ebitda-$-840K-$-1.06M$170K
Operating income-$-840K-$-1.06M-$-30K
Total other income/expenses, net$1.9M$3.62M$200K
Income before tax$1.06M$2.55M$170K
Income tax expense$0.00$0.00$0.00
Net income$1.06M$2.55M$170K
Weighted average shares outstanding$4.05M$9.03M$9.03M
Weighted average diluted shares outstanding$4.05M$9.03M$9.03M
Balance sheet
202520242023
Cash and short-term investments$0.00$30K$580K
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$0.00$30K$580K
Property, plant and equipment, net$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$12.1M$73.8M$69.9M
Total non-current assets$12.1M$73.8M$69.9M
Total assets$12.1M$73.8M$70.5M
Accounts payable$0.00$0.00$0.00
Short-term debt$2.02M$230K$0.00
Deferred revenue$0.00$0.00$0.00
Total current liabilities$3.37M$820K$20K
Long-term debt$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$690K$690K$690K
Capital lease obligations$0.00$0.00$0.00
Total liabilities$4.06M$1.51M$710K
Common stock$12.1M$73.8M$69.9M
Retained earnings-$-4.06M-$-1.48M-$-130K
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$8.04M$72.3M$69.8M
Total investments$12.1M$73.8M$69.9M
Total debt$2.02M$230K$0.00
Net debt$2.02M$200K-$-580K
Cash flow statement
202520242023
Net income$1.06M$2.55M$170K
Depreciation and amortization$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00
Change in working capital$270K$390K$20K
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00
Net cash provided by operating activities-$-570K-$-670K$0.00
Investments in property, plant and equipment$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities$63.6M-$-280K-$-69.69M
Common stock issued$0.00$0.00$70.3M
Common stock repurchased-$-65.33M$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities-$-63.04M$400K$70.3M
Net change in cash-$-30K-$-550K$580K
Cash at end of period$0.00$30K$580K
Operating cash flow-$-570K-$-670K$0.00
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-570K-$-670K$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aimei Health Technology Co., Ltd

        Aimei Health Technology Co., Ltd presently has no significant ongoing business activities. Its main goal is to complete a strategic consolidation, such as a merger, stock swap, asset purchase, equity acquisition, financial restructuring, or another similar business combination, involving one or more companies or organizations. The firm plans to acquire entities primarily in the biopharmaceutical, medical technology/device, diagnostics, and other service-related industries. Founded in 2023, Aimei Health Technology Co., Ltd is based in New York City.

        CEO
        Junheng Xie
        Employees
        2
        Beta
        -0.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Aimei Health Technology Co., Ltd (AFJKR)?

        InvestorsCraft does not currently publish an intrinsic value for AFJKR. How the IC value is calculated.

        Is AFJKR undervalued?

        InvestorsCraft does not publish an undervaluation signal for AFJKR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.